Paul Castella

CardioSpectra, Inc. manufactures and supplies medical devices. The company specializes in optical imaging, interventional cardiology, medical devices and materials science.It develops products for detection of vulnerable plaque, glaucoma, macular degeneration, diabetic retinopathy and cancer. CardioSpectra was founded by Marc D. Feldman & Thomas Milner in 2005 and is headquartered in San Antonio, TX.

Aeon Bioscience, Inc. develops drug-eluting polymers and stents that overcome concerns of late stent thrombosis. It addresses the medical challenges for cardiac patients. The company was founded by Christopher E. Banas and Paul Castella on January 29, 2007 and is headquartered in Birmingham, AL.

Incyte Venture Partners LLC (Incyte Venture Partners) is a venture capital firm founded in 2009. The firm is headquartered in San Antonio, Texas.

ViroXis Corp. develops and commercializes bio-pharmaceuticals derived from sandalwood oils for viral diseases. The company was founded in 2006 by Ian William David Clements and Paul Castella and is headquartered in San Antonio, TX.

Targeted Technology Ventures LLC operated as a biotechnology company. The company was founded by Paul Castella and Christopher E Banas and was headquartered in San Antonio, TX.

BiO2 Medical, Inc. engages in the design, development, and manufacturing of clinical products. The company was founded by Luis F. Angel, Christopher E. Banas, and Paul Castella in December 2006 and is headquartered in Golden, CO.

StemBioSys, Inc. develops stem cell technologies. The firm develops technology on the isolation and expansion of specialized adult stem cells for clinical use. Its technology is called XC-marrowECM, which is a patented extracellular matrix laid down by human bone marrow mesenchymal stem cells. The company was founded by Xiao-Dong Chen and Steven A. Davis in 2010 and is headquartered in San Antonio, TX.

BioDtech, Inc. enagages in the development and marketing of products for the detection, neutralization, and removal of endotoxin. It serves the bioresearch and bioprocess markets. The company was founded by Ira Weiss and Michael G. Pepe in September 2003 and is headquartered in Birmingham, AL.

Innovative Trauma Care, Inc. develops and markets medical devices for traumatic injuries. It is an early stage medical device company focused on developing and marketing solutions to address the common causes of preventable death in traumatic injury scenarios. The firm's product iTClamp Hemorrhage Control System is a temporary wound closure device to control severe bleeding within seconds of application to a penetrating injury. Its product iTClamp seals the edges of a wound closed to create a temporary pool of blood under pressure, which forms a stable clot that mitigates further blood loss until the wound can be surgically repaired. The company was founded by Ian Joseph Atkinson and Dennis Frank Filips in 2010 and is headquartered in San Antonio, TX.